PURPOSE: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients. EXPERIMENTAL DESIGN: Serum from 150 OC patients was tested using SELDI-TOF-MS. RESULTS: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy. CONCLUSIONS AND CLINICAL RELEVANCE: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.
PURPOSE: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients. EXPERIMENTAL DESIGN: Serum from 150 OC patients was tested using SELDI-TOF-MS. RESULTS: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy. CONCLUSIONS AND CLINICAL RELEVANCE: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.
Authors: Mariette Labots; Lisette M Schütte; Johannes C van der Mijn; Thang V Pham; Connie R Jiménez; Henk M W Verheul Journal: Oncologist Date: 2014-09-03
Authors: Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry Journal: Cancer Causes Control Date: 2017-01-03 Impact factor: 2.506
Authors: C M Nagle; S C Dixon; A Jensen; S K Kjaer; F Modugno; A deFazio; S Fereday; J Hung; S E Johnatty; P A Fasching; M W Beckmann; D Lambrechts; I Vergote; E Van Nieuwenhuysen; S Lambrechts; H A Risch; M A Rossing; J A Doherty; K G Wicklund; J Chang-Claude; M T Goodman; R B Ness; K Moysich; F Heitz; A du Bois; P Harter; I Schwaab; K Matsuo; S Hosono; E L Goode; R A Vierkant; M C Larson; B L Fridley; C Høgdall; J M Schildkraut; R P Weber; D W Cramer; K L Terry; E V Bandera; L Paddock; L Rodriguez-Rodriguez; N Wentzensen; H P Yang; L A Brinton; J Lissowska; E Høgdall; L Lundvall; A Whittemore; V McGuire; W Sieh; J Rothstein; R Sutphen; H Anton-Culver; A Ziogas; C L Pearce; A H Wu; P M Webb Journal: Br J Cancer Date: 2015-07-07 Impact factor: 7.640
Authors: Bethany Geary; Erin Peat; Sarah Dransfield; Natalie Cook; Fiona Thistlethwaite; Donna Graham; Louise Carter; Andrew Hughes; Matthew G Krebs; Anthony D Whetton Journal: Cancers (Basel) Date: 2021-05-18 Impact factor: 6.639